SQZ Biotechnologies Company (SQZB)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Howard Bernstein M.D., Ph.D. | Interim CEO & Director | 552.14k | -- | 1957 |
| Mr. Lawrence J. Knopf Esq. | General Counsel & Secretary | 512.38k | -- | 1962 |
| Dr. Marshelle Smith Warren M.D. | Chief Medical Officer | 476.27k | -- | 1964 |
| Dr. Robert S. Langer Jr., Ph.D. | Co-Founder & Member of Scientific Advisory Board | -- | -- | 1949 |
| Mr. Richard V. Capasso CPA | Chief Accounting Officer | -- | -- | 1962 |
| Mr. David First | Chief People Officer | -- | -- | 1964 |
| Ipsita Roymoulik Ph.D. | Senior Vice President of CMC & QUALITY | -- | -- | -- |
SQZ Biotechnologies Company
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 53
Description
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.
Corporate Governance
Upcoming Events
August 8, 2024 at 10:59 AM UTC - August 12, 2024 at 12:00 PM UTC
SQZ Biotechnologies Company Earnings Date
Recent Events
January 4, 2024 at 12:00 AM UTC
15-12G: Notice of termination of registration of a class of securities under Section 12(g)